Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Laboratory Corp of America (LH)  
$201.32 0.05 (0.02%) as of 4:30 Wed 5/1


Download
   
Exchange: New York Stock Exchange
Security Type: Common
Shares Out: 97,400,000
Market Cap: 19.61(B)
Last Volume: 765,348 Avg Vol: 762,523
52 Week Range: $197.69 - $241.33
Level I Sector: Health Care
Level II Sector: Health Services
Level III Sector: Medical Laboratories & Research

Member Indexes:
    S&P COMPOSITE 1500     NYSE COMPOSITE
    S&P 500

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  274
Guru Rank Value     : 4.4
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Laboratory Corporation of America Holdings is a life sciences company that provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. Co. reports its business in two segments, LabCorp Diagnostics (Dx) and Labcorp Drug Development (DD). Dx is an independent clinical laboratory business. It provides a menu of requested and specialty testing through a network of primary and specialty laboratories across the U.S. DD provides drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 44
Total Buy Value $0 $0 $0 $10,251
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 54,498 55,882 66,894 137,120
Total Sell Value $11,803,667 $12,095,294 $14,461,869 $31,164,181
Total People Sold 5 6 8 8
Total Sell Transactions 10 11 15 25
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 933
  Page 9 of 38  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2022-11-07 4 D $233.77 $208,990 D/D (894) 7,803     -
   Caveney Brian J EVP, President of Diagnostics   •       •      –    2022-11-05 4 OE $0.00 $0 D/D 2,010 16,292     -
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2022-11-05 4 OE $0.00 $0 D/D 2,010 8,697     -
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2022-11-01 4 D $222.56 $1,190,251 D/D (5,348) 33,842     -
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2022-11-01 4 OE $0.00 $0 D/D 12,032 39,190     -
   Kirchgraber Paul R CEO, Covance Drug Development   •       •      –    2022-11-01 4 D $222.56 $198,524 D/D (892) 13,030     -
   Kirchgraber Paul R CEO, Covance Drug Development   •       •      –    2022-11-01 4 OE $0.00 $0 D/D 2,007 13,922     -
   Schechter Adam H President & CEO   •       •      –    2022-11-01 4 D $222.56 $198,746 D/D (893) 17,588     -
   Schechter Adam H President & CEO   •       •      –    2022-11-01 4 OE $0.00 $0 D/D 2,007 18,481     -
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2022-09-26 4 AS $209.29 $5,265,576 D/D (25,000) 27,158 20%     
   Caveney Brian J EVP, President of Diagnostics   •       •      –    2022-09-07 4 B $231.20 $10,251 D/D 44 14,282 2.74 9%     
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2022-08-03 4 S $253.27 $8,151,449 D/D (32,100) 52,158 9%     
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2022-08-03 4 OE $130.60 $4,722,543 D/D 32,100 84,258     -
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2022-08-01 4 D $257.94 $5,933 D/D (23) 1,914     -
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2022-08-01 4 OE $0.00 $112,435 D/D 817 1,937     -
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2022-08-01 4 S $258.31 $665,635 D/D (2,576) 1,887 12%     
   Van Der Vaart Sandra D EVP, Chief Legal Officer   •       •      –    2022-03-29 4 AS $277.11 $678,642 D/D (2,449) 5,287 -8%     
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2022-03-29 4 AS $277.11 $652,871 D/D (2,356) 6,605 -8%     
   Wilkinson Peter J SVP, Chief Accounting Officer   •       •      –    2022-03-28 4 D $276.42 $252,924 D/D (915) 3,696     -
   Caveney Brian J EVP, President of Diagnostics   •       •      –    2022-03-28 4 D $276.42 $520,499 D/D (1,883) 14,130     -
   Eisenberg Glenn A Chief Financial Officer, EVP   •       •      –    2022-03-28 4 D $276.42 $1,737,576 D/D (6,286) 52,158     -
   Kirchgraber Paul R CEO, Covance Drug Development   •       •      –    2022-03-28 4 D $276.42 $455,540 D/D (1,648) 11,915     -
   Van Der Vaart Sandra D EVP, Chief Legal Officer   •       •      –    2022-03-28 4 D $276.42 $495,345 D/D (1,792) 7,736     -
   Berberian Lance EVP, CIO & CTO   •       •      –    2022-03-28 4 D $276.42 $652,351 D/D (2,360) 19,502     -
   Schroeder Mark S EVP, President-Diagnostics Lab   •       •      –    2022-03-28 4 D $276.42 $521,052 D/D (1,885) 8,961     -
  933 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 38
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us